Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Heel Pain: Diagnosis and Management.

American family physician·2026

Same author

Skin Ulcers: Prevention and Diagnosis of Pressure, Venous Leg, and Arterial Ulcers.

FP essentials·2020

Same author

Skin Ulcers: Wound Management.

FP essentials·2020

Same author

Skin Ulcers: Surgical Management.

FP essentials·2020

Same author

Common Skin Conditions in Children: Neonatal Skin Lesions.

FP essentials·2017

Same author

Common Skin Conditions in Children: Noninfectious Rashes.

FP essentials·2017

Search research articles

Related Experiment Video

Updated: Nov 27, 2025

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

Skin Ulcers: Pharmacotherapy.

Brian Z Rayala¹

¹University of North Carolina School of Medicine Department of Family Medicine, 590 Manning Drive, Chapel Hill, NC 27599.

|December 2, 2020

Summary

This summary is machine-generated.

Systemic therapies offer more benefits for chronic wounds like pressure ulcers and venous leg ulcers (VLUs). Oral pentoxifylline shows promise for VLU healing, while antimicrobial use is reserved for infected wounds.

More Related Videos

Author Spotlight: Exploring Corneal Innate Immunity and Delayed Wound Healing in Diabetic Patients

Author Spotlight: Exploring Corneal Innate Immunity and Delayed Wound Healing in Diabetic Patients

Published on: January 10, 2025

Chessboard-like Burn Wound Healing Model of Mice Based on Digital Heating Device

Chessboard-like Burn Wound Healing Model of Mice Based on Digital Heating Device

Published on: December 27, 2024

Related Experiment Videos

Last Updated: Nov 27, 2025

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

Author Spotlight: Exploring Corneal Innate Immunity and Delayed Wound Healing in Diabetic Patients

Author Spotlight: Exploring Corneal Innate Immunity and Delayed Wound Healing in Diabetic Patients

Published on: January 10, 2025

Chessboard-like Burn Wound Healing Model of Mice Based on Digital Heating Device

Chessboard-like Burn Wound Healing Model of Mice Based on Digital Heating Device

Published on: December 27, 2024

Area of Science:

Wound healing research
Dermatology
Vascular medicine

Background:

Topical therapies for pressure ulcers, venous leg ulcers (VLUs), and arterial ulcers lack clear benefits.
Systemic therapies demonstrate slightly more supporting evidence for chronic wound management.

Purpose of the Study:

To evaluate the efficacy of various therapies for chronic wounds, including pressure ulcers, VLUs, and arterial ulcers.
To review evidence for topical and systemic treatments, pain management, and nutritional support in chronic wound care.

Main Methods:

Literature review of studies on topical and systemic wound therapies.
Analysis of evidence for oral pentoxifylline in VLU treatment.
Assessment of guidelines for antimicrobial use and pain management strategies.

Main Results:

Oral pentoxifylline, alone or with compression, improved VLU healing compared to placebo (off-label use).
Insufficient evidence supports antiseptics or topical antibiotics over nonmedicated dressings for pressure ulcers and VLUs.
Systemic antibiotics are indicated for nonhealing infected wounds unresponsive to initial treatments.

Conclusions:

Systemic therapies may be more beneficial than topical treatments for certain chronic wounds.
Antimicrobial use should be restricted to infected wounds to prevent resistance.
Pain management should initiate with topical agents, progressing to systemic options if needed, with careful consideration of opioid risks.